NASDAQ:TRDA

Entrada Therapeutics Stock Insider Trading

etoro logo Buy TRDA
*Your capital is at risk
$6.58
-0.0600 (-0.90%)
At Close: Jun 03, 2026

Entrada Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -52.38. In total, the insiders bought 1.27M and sold 1.2M TRDA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-52.38
Buy 1.27M shares
Sell 1.2M shares
41% Buy Activity
Moderate Positive Correlation
Sell Signal High Confidence
May 04, 2026

Analysis Breakdown:

  • Strongly supported by a very low Insider Power Score of -52.38.
  • Partially supported by a positive historical correlation.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
May 20, 2026
Buy
Common Stock
P-Purchase
Zeiher Bernhardt G
Director
Director 5 000
Value: $29.3K
May 04, 2026
Buy
Stock Option (Right to Buy)
M-Exempt
Dowden Nathan J
President & COO
CEO / President 15 000
Value: $26.1K
May 04, 2026
Buy
Common Stock
M-Exempt
Dowden Nathan J
President & COO
CEO / President 15 000
Value: $26.1K
May 04, 2026
Sell
Common Stock
S-Sale
Sethuraman Natarajan
President, Research & Develop.
CEO / President 25 907
Value: $398.8K
May 04, 2026
Sell
Common Stock
S-Sale
Dowden Nathan J
President & COO
CEO / President 15 000
Value: $230.0K
Apr 01, 2026
Sell
Common Stock
S-Sale
Wentworth Kory James
Chief Financial Officer
C-Suite Officer 2 500
Value: $32.4K
Mar 10, 2026
Sell
Common Stock
S-Sale
Dowden Nathan J
President & COO
CEO / President 11 894
Value: $155.2K
Mar 10, 2026
Sell
Common Stock
S-Sale
Wentworth Kory James
Chief Financial Officer
C-Suite Officer 11 388
Value: $148.2K
Mar 09, 2026
Sell
Common Stock
S-Sale
Wentworth Kory James
Chief Financial Officer
C-Suite Officer 5 089
Value: $66.2K
Mar 09, 2026
Sell
Common Stock
S-Sale
Dowden Nathan J
President & COO
CEO / President 3 116
Value: $40.6K
Mar 04, 2026
Sell
Common Stock
S-Sale
Wentworth Kory James
Chief Financial Officer
C-Suite Officer 7 988
Value: $97.9K
Mar 03, 2026
Sell
Common Stock
F-InKind
Sethuraman Natarajan
President, Research & Develop.
CEO / President 7 577
Value: $89.1K
Mar 03, 2026
Sell
Common Stock
F-InKind
Doshi Dipal
CEO
CEO / President 19 181
Value: $225.5K
Mar 03, 2026
Sell
Common Stock
F-InKind
Wentworth Kory James
Chief Financial Officer
C-Suite Officer 5 712
Value: $67.2K
Mar 03, 2026
Sell
Common Stock
F-InKind
Dowden Nathan J
President & COO
CEO / President 14 038
Value: $165.0K
Mar 02, 2026
Sell
Common Stock
F-InKind
Dowden Nathan J
President & COO
CEO / President 7 223
Value: $84.2K
Mar 02, 2026
Sell
Common Stock
F-InKind
Wentworth Kory James
Chief Financial Officer
C-Suite Officer 2 939
Value: $34.3K
Mar 02, 2026
Sell
Common Stock
F-InKind
Doshi Dipal
CEO
CEO / President 9 869
Value: $115.1K
Mar 02, 2026
Sell
Common Stock
F-InKind
Sethuraman Natarajan
President, Research & Develop.
CEO / President 3 898
Value: $45.4K
Mar 01, 2026
Buy
Common Stock
A-Award
Sethuraman Natarajan
President, Research & Develop.
CEO / President 55 800
Value: $367.2K
Mar 01, 2026
Buy
Stock Option (Right to Buy)
A-Award
Dowden Nathan J
President & COO
CEO / President 83 200
Value: $992.6K
Mar 01, 2026
Buy
Stock Option (Right to Buy)
A-Award
Wentworth Kory James
Chief Financial Officer
C-Suite Officer 66 600
Value: $794.5K
Mar 01, 2026
Buy
Stock Option (Right to Buy)
A-Award
Doshi Dipal
CEO
CEO / President 208 000
Value: $2.48M
Mar 01, 2026
Buy
Common Stock
A-Award
Doshi Dipal
CEO
CEO / President 139 400
Value: $917.3K
Mar 01, 2026
Buy
Common Stock
A-Award
Wentworth Kory James
Chief Financial Officer
C-Suite Officer 44 600
Value: $293.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT ENTRADA THERAPEUTICS, INC.
Entrada Therapeutics
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also eng...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE